GLP-2: The Emerging Gut Health Peptide (Research Review)
GLP-2 is released from the same intestinal L-cells as GLP-1 and cleaved from the same proglucagon precursor, but its biology is different: it is a trophic hormone for the intestinal lining. It has an approved analog with real clinical trial data, which puts it in a rare category among peptides discussed in longevity circles.
What GLP-2 Is and Where It Comes From
Glucagon-like peptide-2 is a 33-amino-acid hormone secreted by enteroendocrine L-cells in the distal small intestine and colon in response to nutrient intake. It is produced by post-translational processing of proglucagon — the same precursor that yields GLP-1. Native GLP-2 is degraded within minutes by DPP-4, which is why the approved analog, teduglutide, carries a single amino acid substitution that resists that enzyme.
Mechanism: Intestinal Growth and Barrier Integrity
GLP-2 binds the GLP-2 receptor, expressed not on enterocytes directly but on subepithelial myofibroblasts, enteric neurons and enteroendocrine cells. Signaling propagates through mediators including IGF-1 and keratinocyte growth factor, producing increased crypt cell proliferation, reduced enterocyte apoptosis, greater villus height, increased mesenteric blood flow, and tightened epithelial junctions.
Why barrier function matters
A compromised intestinal barrier permits bacterial products such as lipopolysaccharide to reach systemic circulation, which is a recognized driver of low-grade chronic inflammation. That inflammatory tone is one of the mechanistic threads connecting gut integrity to age-related disease — the reason GLP-2 appears in longevity discussion at all.
How it differs from GLP-1
GLP-1 acts primarily on pancreatic insulin secretion, gastric emptying and central appetite regulation. GLP-2 has essentially no incretin effect and does not suppress appetite. Same precursor, different receptor, different job.
The Clinical Evidence: Teduglutide
Teduglutide is FDA-approved for short bowel syndrome in patients dependent on parenteral support. In pivotal trials, a significantly greater proportion of treated patients achieved a 20% or greater reduction in weekly parenteral support volume versus placebo, with effects sustained across extension studies. This is genuine, regulator-reviewed evidence — for one narrow indication in a patient population with severe intestinal failure.
Where Speculation Starts
Every claim about GLP-2 for general gut health, athletic gut permeability, autoimmune modulation or longevity is extrapolation from a short bowel syndrome indication. That extrapolation is mechanistically coherent and completely untested. It also carries a specific theoretical risk: a hormone that stimulates crypt cell proliferation is a hormone that could in principle promote growth of existing intestinal neoplasia, which is why teduglutide labeling requires colonoscopy screening before and during treatment.
Safety Considerations
Documented adverse effects from the approved analog include abdominal pain and distension, nausea, injection site reactions, stoma complications, fluid overload, and biliary or pancreatic events requiring monitoring. The colorectal polyp screening requirement is the most consequential item for anyone considering off-label use without physician oversight, because it is the one risk that is silent until it is not.
Verification: Why This Peptide Is a Hard Target
GLP-2 and its analogs are long sequences that are expensive to synthesize correctly. In our sample testing, longer sequences correlate with higher rates of truncated or deletion-sequence impurities — a peptide that is 60% correct product and 40% failed synthesis fragments still looks like white powder in a vial. Mass spectrometry identifies the sequence; HPLC quantifies how much of the contents are actually that sequence.
Frequently Asked Questions
Is GLP-2 the same as GLP-1?
No. They come from the same proglucagon precursor but bind different receptors. GLP-1 affects insulin, gastric emptying and appetite; GLP-2 promotes intestinal growth and barrier integrity.
Is any GLP-2 drug approved?
Yes — teduglutide, a DPP-4-resistant GLP-2 analog, is approved for short bowel syndrome with dependence on parenteral support.
Does GLP-2 help leaky gut?
There are no trials in healthy adults or in people with non-specific intestinal permeability. The mechanism is plausible; the evidence does not exist.
References
Report a Safety Issue
If you've experienced health issues after using this peptide, please report it. Your report helps us track safety issues and protect other users.
Report Adverse Event